Home › Growth › Ipamorelin (10mg)
Growth Research Peptide
Selective GH secretagogue · GHS-R1a agonist · Research-grade, Australia
In stock · dispatched Australia-wide
View & buy on store →Ipamorelin is a synthetic pentapeptide that acts as a selective growth hormone secretagogue, functioning as an agonist at the ghrelin receptor (GHS-R1a). It is distinguished in the research literature by its selectivity: published pre-clinical work reports it stimulates GH release without significantly elevating cortisol, prolactin, or ACTH, unlike earlier secretagogues in its class.
This 10mg presentation is the larger of the two we offer and is intended for extended laboratory study protocols. It is supplied by Vital Research Labs strictly as a reference compound for in-vitro laboratory investigation.
| Compound | Ipamorelin |
|---|---|
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Category | Growth |
| CAS Number | 170851-70-4 |
| Length | 5 amino acids (pentapeptide) |
| Molecular weight | 711.85 g/mol |
| Form | Lyophilised powder |
| Appearance | White to off-white solid |
| Quantity | 10 mg per vial |
| Purity | N/A — Certificate of Analysis pending |
| Analytical methods | HPLC (purity), mass spectrometry (identity) |
| Solubility (research) | Reconstitutes in bacteriostatic or sterile water |
Batch-specific analytical values will be recorded on the Certificate of Analysis for this batch, which is pending.
Ipamorelin is supplied as a lyophilised (freeze-dried) powder. For research handling it is typically reconstituted with bacteriostatic water; the exact volume depends on the concentration a given research protocol calls for. Our reconstitution calculator can be used to work out volumes for a target research concentration. Handle under appropriate laboratory conditions and avoid repeated freeze–thaw cycles of the reconstituted solution.
Every batch supplied by Vital Research Labs is analysed by an independent third-party laboratory, with purity confirmed by HPLC and identity by mass spectrometry. Testing for this batch is currently in progress; the Certificate of Analysis will be published in our CoA library once received. We do not publish purity figures we cannot evidence.
Ipamorelin is dispatched from within Australia to Australian research customers, packaged discreetly and appropriately for a lyophilised research compound. Orders are processed on receipt of payment via bank transfer.
The compound is identical; only the quantity of lyophilised powder per vial differs. The 10mg presentation is intended for extended research protocols requiring more material, and offers a lower cost per milligram.
Published pre-clinical research reports that Ipamorelin stimulates growth hormone release without significantly raising cortisol, prolactin or ACTH, which distinguishes it from earlier growth hormone secretagogues studied in the same class.
They act on different receptors. Ipamorelin is an agonist at the ghrelin receptor (GHS-R1a), while CJC-1295 No DAC is a GHRH analogue acting at the GHRH receptor. The two pathways are complementary, which is why they are frequently studied together.
Testing for this batch is currently in progress. Purity is shown as N/A until the Certificate of Analysis is received, at which point it is published in our CoA library. We do not publish purity figures we cannot evidence.
The lyophilised powder is stored at -20 degrees C, protected from light and moisture. Once reconstituted for research it is kept at 2-8 degrees C and typically used within 28 days.
No. It is intended strictly for in-vitro laboratory research and development. It is not a medicine or therapeutic good and is not for human consumption, veterinary use, or clinical application.